| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Infectious Diseases | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Infectious Diseases | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Infectious Diseases |
Recent Updates
Recently added Catalysts
Vir Biotechnology, Inc.$9.96
-0.39 (-3.77%)
C 57Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.55 B
EPS
-3.14
P/E Ratio
-
Value Trade
20.82 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-29.00 K
R&D Expenses
108.92 M
Operating CF
-132.39 M
Total Assets
1.03 B
Total Liabilities
212.82 M
Equity
812.76 M
D/E Ratio
12,345
2.57 %
Week
-15.3 %
1 Month
19.66 %
3 Month
65.29 %
6 Month
-80 %
5 Year
-43.1 %
All Time
Cash Data
Cash Position
470.44 M
Monthly Burn
44.13 M
Runway
8.8 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.68 M
52 Week Range
4.16 - 11.66
% held by Insiders
20.97 %
% held by Institutions
63.76 %
Enterprise Value
1.17 B
Total Shares
168.54 M
Short %
14.67 %
Float Shares
130.79 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vir Biotechnology, Inc.
527Total events
3Upcoming
155Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 3
Event history 524
Jun 10, 2026
May 6, 2026
May 5, 2026
●Oral PresentationPresentation
Vir Biotechnology to participate in Bank of America Securities 2026 Healthcare Conference
Apr 17, 2026
▲Partnership / LicenseVIR-5500Corporate
Global strategic collaboration with Astellas closed
metastatic prostate cancersource ↗
Apr 17, 2026
▲Milestone PaymentVIR-5500Corporate
Near-term $20 million milestone payment upon closing
metastatic prostate cancersource ↗
Apr 16, 2026
▲Partnership / LicenseCorporate
Closing of global strategic collaboration with Astellas for prostate cancer
prostate cancersource ↗
Apr 14, 2026
▲First Patient DosedVIR-5500Trial
First patient dosed in Phase 1 dose-expansion cohort (monotherapy) for VIR-5500
metastatic prostate cancersource ↗
Apr 13, 2026
▲First Patient DosedVIR-5500Trial
First patient dosed in Phase 1 dose-expansion cohorts of VIR-5500
metastatic prostate cancersource ↗
Q2 2026
◆Trial InitiationVIR-5500Trial
Initiation of combination dose-expansion cohorts in early-line mCRPC and mHSPC
metastatic castration-resistant prostate cancersource ↗
Feb 26, 2026
▼Equity OfferingCorporate
Pricing of underwritten public offering of 17,647,058 shares at $8.50 per share for gross proceeds of $150 million
Drug Pipeline Intelligence
C57
Pipeline Score $1.9B
Pipeline ValueFair Value
Valuation Signal14
Drugs Scored1.3x
rNPV / MCap Top 84%
Micro Cap (rank 147 of 911)
Percentile RankVir Biotechnology, Inc. carries a moderate pipeline score (57/100), with $6.5B risk-adjusted pipeline value, led by Tobevibart in Viral Hepatitis (Phase 3), across $131B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tobevibart Small molecule | Viral Hepatitis | Phase 3 | NCT07142811 | 56% | $2.5B | ACTIVE NOT_RECRUITING | 374 | FAST | C (49) | Jul 1, 2030 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VIR-5500 | metastatic prostate cancer | Phase 1 | 2026-02-24 | PSA50 declines: 82%; PSA90 declines: 53%; ORR: 45% | Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer Read More | |
VIR-5500 | metastatic prostate cancer | Phase 1 | 2026-02-24 | PSA50 declines: 82%; PSA90 declines: 53%; ORR: 45% | Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer Read More | |
VIR-5500 | metastatic prostate cancer | Phase 1 | 2026-02-24 | PSA50 declines: 82%; PSA90 declines: 53%; ORR: 45% | Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VIR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VIR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VIRVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology has appointed Timothy Coughlin to its Board of Directors. Coughlin's extensive experience in the biopharma industry is expected to enhance the company's leadership. This strategic move aims to bolster the company's governance and support its future initiatives.
Read more →VIRVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology will present complete data from the Phase 2 SOLSTICE clinical trial focused on Hepatitis Delta at the EASL Congress 2026. This presentation is expected to provide insights into the trial's findings and implications for future research. The event highlights the company's ongoing commitment to addressing Hepatitis Delta.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology has released a corporate update along with its financial results for the first quarter of 2026. The article provides insights into the company's performance and strategic direction. However, specific details regarding financial metrics or corporate strategies are not disclosed in the provided text.
Read more →VIRVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology will participate in the Bank of America Securities 2026 Healthcare Conference. This event provides a platform for the company to discuss its strategies and advancements in biotechnology. Further details about the conference agenda and Vir's specific contributions are yet to be announced.
Read more →VIRVir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
Vir Biotechnology, Inc. will host a conference call on May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter ending March 31, 2026. The call will provide a corporate update and can be accessed via the company's website. Vir is focused on developing treatments for infectious diseases and cancer.
Read more →VIRVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
Vir Biotechnology has finalized a global collaboration with Astellas for the development and commercialization of VIR-5500, a T-cell engager for metastatic prostate cancer. The agreement includes a $240 million upfront payment and potential milestone payments totaling up to $1.37 billion. Astellas will lead commercialization efforts in the U.S., while Vir retains co-promotion rights. The collaboration aims to enhance the drug's development towards market readiness.
Read more →VIR▲ +7.9%on this newsshared move
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Vir Biotechnology has initiated the dosing of the first patient in its Phase 1 trial for VIR-5500, a T-cell engager targeting metastatic prostate cancer. This trial will assess the safety and efficacy of VIR-5500 as both a monotherapy and in combination with an androgen receptor pathway inhibitor. The company is optimistic about the treatment's potential, supported by encouraging data from earlier studies.
Read more →VIRVir Biotechnology to Participate in Upcoming March 2026 Investor Conferences
Vir Biotechnology, Inc. has announced its participation in several investor conferences scheduled for March 2026. The management team will engage in live webcasts, which will be available for 30 days post-event. The company focuses on developing treatments for infectious diseases and cancer, showcasing its commitment to innovation in biopharmaceuticals.
Read more →VIR▼ -6.8%on this newsshared move
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Vir Biotechnology has announced the pricing of its public offering of 17,647,058 shares at $8.50 each, aiming to raise $150 million. The offering includes a 30-day option for underwriters to purchase additional shares. The closing is expected on February 27, 2026, pending customary conditions. This move supports Vir's mission to develop treatments for serious infectious diseases and cancer.
Read more →VIR▲ +5.4%on this newsshared move
Vir Biotechnology Announces Proposed Public Offering of Common Stock
Vir Biotechnology, Inc. has announced a proposed public offering of $200 million in common stock, with an additional $30 million option for underwriters. The offering is part of their strategy to fund clinical programs targeting serious infectious diseases and cancer. The terms and completion of the offering depend on market conditions.
Read more →VIR▲ +27.7%on this newsshared move
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Vir Biotechnology announced a strategic collaboration with Astellas to enhance the development of its PSMA-targeted T-cell engager, VIR-5500, for prostate cancer. The company reported positive Phase 1 data indicating a favorable safety profile and anti-tumor activity. Despite a net loss of $(438.0) million for 2025, Vir maintains a strong financial position with $781.6 million in cash and investments.
Read more →VIR▲ +27.7%on this newsshared move
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Vir Biotechnology reported positive updated Phase 1 results for VIR-5500, a T-cell engager targeting metastatic prostate cancer. The treatment demonstrated a favorable safety profile with no dose-limiting toxicities and significant anti-tumor activity, including 82% PSA50 and 53% PSA90 declines. The company plans to advance to dose-expansion cohorts and initiate a registrational trial in 2027.
Read more →VIRAstellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - Astellas and Vir Biotechn
Astellas Pharma and Vir Biotechnology have formed a global strategic collaboration to co-develop and commercialize VIR-5500, a PSMA-targeting T-cell engager for the treatment of prostate cancer. The deal involves Vir receiving $335 million upfront and additional milestone payments potentially totaling $1.37 billion. Astellas will lead the commercialization efforts in the U.S., while sharing profits and development costs. The collaboration aims to leverage Astellas' oncology expertise to advance this promising treatment option.
Read more →VIRVir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
Vir Biotechnology, Inc. will host a conference call on February 23, 2026, to discuss its financial results for the fourth quarter and full year ending December 31, 2025. The call aims to provide a corporate update and is accessible via the company's website. Vir Biotechnology focuses on developing treatments for infectious diseases and cancer.
Read more →VIRVir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Vir Biotechnology will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14. CEO Marianne De Backer will lead the presentation, which will be available via live webcast. The company focuses on developing treatments for serious infectious diseases and cancer, with a strong clinical-stage portfolio.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results - ECLIPSE 1 enrollment completed approximately two months ahead of schedule ECLIPSE 2 and ECLIPSE 3 progressing with strong enr
Vir Biotechnology provided a corporate update alongside its third quarter 2025 financial results. Notably, the enrollment for the ECLIPSE 1 trial was completed about two months earlier than anticipated, with ECLIPSE 2 and 3 studies also progressing well. Financially, the company maintains a strong cash position of approximately $810.7 million, though it reported a net loss of $163.1 million for the quarter. Upcoming topline data for multiple studies are slated for the first quarter of 2027, indicating a robust development pipeline.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - ECLIPSE registrational program in chronic hepatitis delta fully underway - First patient dosed in Phase 1 study of VIR-5525,
Vir Biotechnology announced the initiation of their ECLIPSE registrational program for chronic hepatitis delta and reported strong financial results for Q2 2025, including $892.1 million in cash. The company also dosed the first patient in its Phase 1 clinical study for VIR-5525, an investigational treatment targeting solid tumors. While the company is optimistic about its pipeline and ongoing clinical trials, it reported decreased revenues and a significant net loss compared to the previous year. The company's financial position is expected to sustain operations through mid-2027.
Read more →VIR▼ -6%on this news· ran to -17% by day 3
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study - HBsAg loss 24 weeks post-end of treatment achieved in 17%
Vir Biotechnology has announced preliminary data from the MARCH Phase 2 study, revealing that 17% and 21% of participants achieved HBsAg loss 24 weeks after treatment with tobevibart and elebsiran. The results were highlighted at the EASL congress, indicating promising efficacy among a subset of chronic hepatitis B patients. Despite these positive findings, Vir stated it will not progress to Phase 3 without securing a global partnering deal for commercialization. The company plans to streamline the trial process while maintaining financial oversight and continues to focus on chronic hepatitis delta treatment development.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025 Program re
Vir Biotechnology provided a corporate update and reported first quarter financial results for 2025, highlighting the initiation of its Phase 3 ECLIPSE program in chronic hepatitis delta and the enrollment of its first patient. The company continues to progress in its oncology pipeline with encouraging data for dual-masked T-cell engagers. Despite a significant drop in quarterly revenues, the company maintains a strong financial position with over $1 billion in cash reserves, ensuring a runway into 2027. Key future presentations and studies are scheduled, including data from the MARCH study and the initiation of a new Phase 1 trial.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half
Vir Biotechnology reported a corporate update and financial results for Q4 and full year 2024. The company is on track to begin its Phase 3 ECLIPSE clinical program for chronic hepatitis delta in the first half of 2025. Regulators granted breakthrough and orphan drug designations for key therapies to expedite development. However, the financial report revealed a significant decline in cash reserves and revenue compared to the previous year, indicating potential concerns about financial stability.
Read more →VIR▲ +58.2%on this news
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC Compelling early clinical response signals
Vir Biotechnology presented promising Phase 1 data on two dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting solid tumors and metastatic castration-resistant prostate cancer, respectively. The data, revealing encouraging safety and efficacy profiles, indicated no dose-limiting cytokine release syndrome and early signs of tumor shrinkage in participants. With ongoing dose escalation and preliminary results suggesting well-tolerated treatment, these findings could address significant unmet medical needs in cancer therapy.
Read more →VIRVir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Successful closing of exclusive worldwide licensing agreement with Sanofi for three potential best-in-class clinical-stage du
Vir Biotechnology provided a corporate update along with its Q3 2024 financial results. The highlights include a successful licensing agreement with Sanofi for best-in-class T-cell engagers, with initial clinical data expected by Q1 2025. The company presented optimistic Phase 2 data for its hepatitis treatments and announced the appointment of Jason O'Byrne as the new CFO. However, Vir also navigated challenges such as a 25% workforce reduction and decreased revenue compared to the previous year.
Read more →VIRVir Biotechnology announces closing of exclusive worldwide license agreement with Sanofi for multiple potential best-in-class clinical-stage T-Cell engagers - License of proprietary masking platform further strengthens V
Vir Biotechnology has finalized an exclusive worldwide license agreement with Sanofi for clinical-stage T-cell engagers, which could enhance treatment options for various cancers. The agreement includes three specific assets currently in phase 1 trials targeting different tumor types. Additionally, the proprietary PRO-XTEN masking platform will allow for potentially safer and more effective therapies. Key Sanofi employees with expertise in T-cell engagers will join Vir to facilitate the transition and development of these assets.
Read more →VIRVir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities - Positive preliminary Phase 2 chronic hepatitis delta study data
Vir Biotechnology reported its second-quarter financial results for 2024, showcasing promising preliminary data from a Phase 2 chronic hepatitis delta study. The company received FDA IND clearance and Fast Track designation for its combination therapy, marking significant progress in addressing unmet medical needs. Alongside this, Vir is restructuring to focus on high-value clinical-stage opportunities, which includes a workforce reduction of 25%. The company reported $1.43 billion in cash and investments, despite a net loss of $138.4 million for the quarter.
Read more →VIRVir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection Fast Track designation follows positive preliminary Phase 2 tria
Vir Biotechnology has received FDA clearance for its investigational new drug (IND) application and Fast Track designation for the treatment of chronic hepatitis delta infection using tobevibart and elebsiran. This follows positive preliminary results from its Phase 2 SOLSTICE trial, which showed high rates of virologic response. The company aims to expedite development and bring this potentially groundbreaking treatment to patients facing this serious disease, highlighting the significant unmet medical need in this area.
Read more →VIR▲ +19.7%on this news
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment Preliminary Phase 2
Vir Biotechnology, Inc. announced promising preliminary data from its Phase 2 SOLSTICE trial regarding tobevibart and elebsiran for chronic hepatitis delta. Treatments demonstrated high rates of virologic response and ALT normalization among participants after 12 and 24 weeks. The company plans to share additional 24-week data for approximately 60 participants later in 2024. Importantly, these findings suggest that tobevibart, both alone and in combination with elebsiran, could potentially provide much-needed options for patients suffering from this severe illness.
Read more →VIR▲ +5%on this news· ran to +19% by day 1
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results - Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (
Vir Biotechnology has provided a corporate update and financial results for Q1 2024, highlighting the acceptance of its late-breaker SOLSTICE trial data for presentation at the upcoming EASL Congress. The company reported a cash position of approximately $1.51 billion, despite a 10.5% decrease in total revenues compared to the same period last year. The leadership expressed optimism about upcoming data readouts on chronic hepatitis treatments and a focus on advancing clinical programs amid a strategic cost management effort. However, revenue declines and net losses indicate ongoing financial challenges.
Read more →VIRVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
Vir Biotechnology has announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors, effective May 29, 2024. This nomination follows a commitment to refresh the board with independent members who bring expertise in clinical development and computational sciences. Dr. Bischofberger has overseen the approval of over 25 medicines in his career, while Dr. Farid has advanced a leading computational platform for drug discovery at Schrödinger. Their addition is expected to bolster Vir's capabilities in treating infectious and viral-associated diseases.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results - Prior data from the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after onl
Vir Biotechnology has provided an update on its corporate activities and financial performance for Q4 and the full year 2023. The company reported promising early results from its Phase 2 SOLSTICE trial in chronic hepatitis delta, with anticipations of completing enrollment ahead of schedule. However, total revenues declined sharply from previous years, raising concerns about financial stability. Vir continues to focus on advancing its clinical programs while navigating significant operational changes.
Read more →VIR▲ +5.1%on this news
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Company to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials - - Company
Vir Biotechnology provided a corporate update alongside its third quarter financial results, reporting $1.7 billion in cash as of September 30, 2023. The company announced plans to present new data from its Phase 2 clinical trials for chronic hepatitis B and delta at the upcoming AASLD meeting. Despite a significant drop in total revenues compared to the previous year, Vir received additional funding from BARDA, supporting its research in RNA-delivered monoclonal antibodies. The appointment of Jennifer Towne as the new Chief Scientific Officer is expected to enhance the company's R&D efforts moving forward.
Read more →VIRVir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
Vir Biotechnology announced its participation in the H.C. Wainwright 4th Annual Hepatitis B Virus Conference. Phil Pang, M.D., Ph.D., will engage in a virtual fireside chat on October 25. The event will be accessible via a live webcast and archived for 30 days on the company's website. Vir is focused on developing treatments for infectious diseases.
Read more →VIRVir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
Vir Biotechnology announced that eight abstracts related to its chronic hepatitis B and hepatitis delta clinical programs have been accepted for presentation at the AASLD The Liver Meeting 2023. This includes seven poster presentations and one late-breaking oral presentation. The company aims to showcase the potential benefits of its investigational therapies, VIR-3434 and VIR-2218, for patients with these conditions.
Read more →VIRVir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
Vir Biotechnology, Inc. will provide a corporate update and report its third quarter financial results on November 2, 2023. The update will be accessible via a press release and a conference call at 4:30 p.m. ET. The company focuses on immunology and has a pipeline targeting multiple infectious diseases.
Read more →VIRVir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
Vir Biotechnology has secured approximately $50 million in funding from BARDA to advance its monoclonal antibody (mAb) candidates and delivery technologies. This funding includes $40 million from Project NextGen aimed at COVID-19 therapeutics. The initiative will support the development of VIR-7229, a promising mAb for COVID-19, and enhance delivery methods for broader application in pandemic response.
Read more →VIRVir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
Vir Biotechnology has initiated a Phase 1 trial for VIR-1388, a novel T cell vaccine aimed at preventing HIV. The trial, supported by the Bill & Melinda Gates Foundation and NIAID, will assess the vaccine's safety and immunogenicity. Initial data is expected in late 2024, marking a significant step in HIV vaccine development.
Read more →VIRVir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
Vir Biotechnology, Inc. announced its participation in several investor healthcare conferences in September 2023. The company will host a live webcast of a fireside chat, which will be available on their website for 30 days. Vir focuses on innovative treatments for infectious diseases and has an extensive clinical pipeline.
Read more →VIRDocument Exhibit-99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results - Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track f
Vir Biotechnology provided a corporate update and financial results for Q2 2023, highlighting ongoing projects and strategic shifts. The Phase 2 data readouts for the hepatitis B and delta programs are expected in Q4 2023, while the company focuses on a proprietary antibody platform. Despite a strong cash position of $1.9 billion, revenue remains low, and the influenza A trial faced setbacks. The initiation of the Phase 1 trial for a new HIV vaccine, VIR-1388, is anticipated in Q3 2023.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Vir Biotechnology, Inc. provided a corporate update and financial results for Q2 2023, highlighting a strong cash position of approximately $1.9 billion. The company is focusing on its monoclonal antibody platform while discontinuing its innate immunity small molecule platform. Upcoming catalysts include data readouts for chronic hepatitis B and delta treatments in Q4 2023 and the initiation of a Phase 1 trial for an HIV vaccine, VIR-1388, expected to begin in Q3 2023. However, the recent PENINSULA trial for VIR-2482 showed disappointing results, and collaboration revenues have seen a significant decline.
Read more →VIRVir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
Vir Biotechnology, Inc. has announced that it will provide a corporate update and report its financial results for the second quarter of 2023 on August 3, 2023. The update will be shared through a press release after market close and will be followed by a conference call at 4:30 p.m. Eastern Time. The company focuses on enhancing the immune system to treat serious infectious diseases, with ongoing development efforts targeting diseases such as hepatitis B, influenza A, and COVID-19.
Read more →VIR▼ -44.9%on this news
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
Vir Biotechnology announced that its Phase 2 PENINSULA trial evaluating VIR-2482 for preventing symptomatic influenza A did not meet its primary or secondary efficacy endpoints. While a 16% reduction in influenza A illness was noted, it was not statistically significant. The drug was well tolerated, and further analysis of the results is planned for presentation at a medical congress.
Read more →VIRVir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
Vir Biotechnology has appointed Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. She will oversee corporate communications, government affairs, and investor relations, reporting to CEO Marianne De Backer. Ellis brings extensive experience from Marinus Pharmaceuticals and Bayer U.S., enhancing Vir's strategic capabilities.
Read more →VIRVir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
Vir Biotechnology presented new data evaluating VIR-2218 and VIR-3434 as therapies for chronic hepatitis B and D during the EASL Congress. Preliminary results from clinical trials indicate a promising rate of HBsAg loss when combining VIR-2218 with pegylated interferon. Furthermore, preclinical data show effectiveness in targeting hepatitis D virus. Overall, the organization expressed optimism about the functional cure potential of these investigational therapies.
Read more →VIRVir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
Vir Biotechnology, Inc. announced that five abstracts showcasing their new hepatitis B and D data have been accepted for presentation at the EASL Congress 2023 in Vienna. The oral presentations will focus on the safety and efficacy of their investigational therapies VIR-2218 and VIR-3434. Initial data from clinical trials suggest potential improvements in treatment outcomes for chronic HBV and HDV infections. The company aims to address the urgent needs of patients with these viral infections through their promising research and development initiatives.
Read more →VIRVir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
Vir Biotechnology, Inc. will have its CEO, Marianne De Backer, participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference. The event is scheduled for June 12, and interested parties can access a live webcast of the presentation. This participation highlights the company's commitment to addressing serious infectious diseases through advanced immunology technologies.
Read more →VIRVir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
Vir Biotechnology, Inc. will host its 2023 Annual General Meeting of Stockholders on May 19, 2023, at 11:30 a.m. PT. The meeting will take place in a virtual format, allowing stockholders to attend through a live audio webcast. Stockholders of record can vote during the meeting by accessing the provided meeting center link. The company encourages stockholders to submit their proxies in advance of the meeting.
Read more →VIRVir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
Vir Biotechnology has announced the appointment of Jeff Calcagno, M.D., as the new Executive Vice President and Chief Business Officer. In this role, Dr. Calcagno will focus on leading business development efforts and strengthening strategic partnerships. He joins Vir from Johnson & Johnson, bringing over 12 years of leadership experience. Dr. Calcagno's expertise, which includes evaluating life sciences companies, is expected to play a crucial role in advancing Vir's mission in treating infectious diseases.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports
Vir Biotechnology provided a corporate update detailing its financial results for Q1 2023, highlighting anticipated data readouts from ongoing Phase 2 trials for hepatitis B, hepatitis D, and influenza. The company reported a significant decrease in total revenues and collaboration revenue compared to the previous year, attributed to lower profit shares from the sale of sotrovimab. Dr. Marianne De Backer has been appointed as CEO, poised to lead the company through its next growth phase, supported by a strong financial position with $2.3 billion in cash. The updates reflect both potential opportunities and ongoing commercialization challenges.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
Vir Biotechnology has provided a corporate update highlighting multiple upcoming Phase 2 data readouts in 2023 for hepatitis B, hepatitis D, and influenza. The company reported a significant drop in its Q1 2023 revenues, totalling $63 million compared to $1.2 billion during the same period last year. Despite the financial challenges, Vir maintains a strong cash position of $2.3 billion and continues to advance its pipeline under new CEO Marianne De Backer. The company is poised for potential therapeutic breakthroughs, especially with the ongoing trials for its investigational drugs.
Read more →VIRVir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
Vir Biotechnology, Inc. has announced its participation in the BofA Securities 2023 Health Care Conference, where CEO Marianne De Backer will present. The presentation is scheduled for May 10 at 8:00 a.m. PT / 11:00 a.m. ET, and investors can access a live webcast on the company's website. Vir Biotechnology is dedicated to developing immunological solutions for serious infectious diseases, with a pipeline targeting multiple viruses.
Read more →VIRVir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
Vir Biotechnology has announced that it has been awarded a $10 million grant from the Bill & Melinda Gates Foundation to support the development of its novel T cell vaccine, VIR-1388, aimed at preventing HIV. This new funding will assist in the Phase 1 clinical trial, which is expected to begin in the latter half of 2023. The vaccine utilizes a human cytomegalovirus vector platform and aims to elicit T cells that recognize different HIV epitopes. Vir's long-standing partnership with the Gates Foundation reflects their commitment to developing solutions for infectious diseases significantly impacting global health.
Read more →VIRVir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Vir Biotechnology, Inc. has announced that Phil Pang, M.D., Ph.D., will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference. The event is scheduled for April 18, and a live webcast of the presentation will be available on Vir's website. This participation emphasizes Vir's dedication to engaging with investors and showcasing its immunology advancements. The company's current development pipeline focuses on significant infectious diseases, including COVID-19 and hepatitis viruses.
Read more →VIRVir Biotechnology to Participate in the Barclays Global Healthcare Conference
Vir Biotechnology, Inc. is set to participate in the Barclays Global Healthcare Conference, where Dr. Phil Pang will present on March 15. The presentation is accessible via a live webcast on the company's website and will remain archived for 30 days. Vir Biotechnology is engaged in developing treatments for various infectious diseases through advanced immunology technology platforms.
Read more →VIRVir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
Vir Biotechnology, Inc. has announced its participation in the Cowen 43rd Annual Health Care Conference. Executive Vice President Bolyn Hubby will join a panel discussion on infectious diseases set for March 7. The event reflects the company's commitment to address critical health issues and engage with industry counterparts. A live webcast of the session will be available for stakeholders.
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Vir Biotechnology provided a corporate update and financial results for 2022, indicating a transformative year ahead with key Phase 2 trials in hepatitis B, hepatitis D, and influenza expected to yield significant data in 2023. The company recognized $1.5 billion in revenue from its collaboration on sotrovimab, while transitioning to new leadership as CEO George Scangos announces his retirement. The robust cash flow and pipeline developments position Vir for continued growth despite leadership changes.
Read more →VIRVir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
Vir Biotechnology received positive final draft guidance from the UK's NICE for sotrovimab, an investigational monoclonal antibody for treating COVID-19 in patients not requiring supplemental oxygen. The guidance recommends sotrovimab for individuals at increased risk of severe disease where other treatments are unsuitable. Despite the favorable guidance, the company anticipates no significant increase in sales in the UK due to existing inventory. Further final recommendations from NICE on COVID-19 treatments are expected in March 2023.
Read more →VIRVir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Vir Biotechnology, Inc. is set to deliver a corporate update and discuss its financial results for Q4 and the full fiscal year 2022 on February 23, 2023. This announcement indicates the company's focus on communicating its financial and operational health to stakeholders. The financial results will be shared via a press release after market close, and further details can be found on the company's website. Vir's ongoing commitment to addressing serious infectious diseases remains a focal point of its activities.
Read more →VIRVir Biotechnology Appoints Sung Lee as Chief Financial Officer
Vir Biotechnology has appointed Sung Lee as Chief Financial Officer, effective March 27, 2023. Lee, who has over 20 years of experience in financial leadership within the biotech sector, will take on this role following the departure of Howard Horn, who will continue in an advisory capacity temporarily. The leadership believes Lee's skills will be vital for the company's growth and ongoing mission to develop innovative treatments for infectious diseases.
Read more →VIRVir Biotechnology Announces Amended Collaboration Agreement with GSK
Vir Biotechnology has amended its collaboration agreement with GSK, allowing Vir to advance next-generation COVID-19 solutions independently while continuing to work jointly on sotrovimab and new therapies for respiratory diseases. This agreement reflects a commitment to providing access to sotrovimab and developing innovative treatments for various viral infections. The partnership updates aim to leverage both companies' strengths in addressing urgent public health needs related to coronaviruses and influenza.
Read more →VIRVir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
Vir Biotechnology announced the retirement of CEO George Scangos, effective April 3, 2023, with Marianne De Backer appointed as his successor. Dr. Scangos will remain in an advisory role until June 2, 2023. Under Scangos, the company experienced significant growth and established a robust therapeutic pipeline. Dr. De Backer, previously at Bayer Pharmaceuticals, comes with extensive industry experience and is expected to lead the company into its next phase of innovation and growth.
Read more →VIRVir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
Vir Biotechnology will discuss its 2023 catalysts and growth strategy at the 41st Annual J.P. Morgan Healthcare Conference. The company anticipates critical Phase 2 readouts for its programs targeting hepatitis B, hepatitis D, and influenza this year. Additionally, Vir's robust financial position is expected to support its development efforts and allow for the exploration of external opportunities. However, various risks related to drug development may impact outcomes.
Read more →VIRVir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR
Read more →VIRVir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
SAN FRANCISCO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first on the 2022 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies
Read more →VIR▲ +6.2%on this news
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
– Data from multiple ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B surface antigen (HBsAg) with no new safety signals – – Preliminary data to-date show that 30.8% of participants receiving 48 weeks of VIR-22
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
- Biomedical Advanced Research and Development Authority (BARDA) awarded contract to support pandemic preparedness for influenza and other infectious diseases; initial investment of ~$55.0 million with potential total of up to $1.0 billion - - Phase 2 data from three of the Comp
Read more →VIRVir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting 2022
SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical program have been accepted for presentation at the American Association for the Study of Live
Read more →VIRVir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022. The corporate update and
Read more →VIRVir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research and Development Authority supporting development of VIR-2482 – SAN FRANCISCO, Oct. 18, 2022
Read more →VIRVir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research, is scheduled to present at the H. C. Wainwright 3rd Annual Hepatitis B
Read more →VIR▲ +7.7%on this news
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats First award from the agency s solicitation for contracts for Pre-Exposure Prophylaxis
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats First award from the agency s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza Initial investment of approximately $55 m
Read more →VIRVir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel combination strategy designed to reduce HDV viremia and block viral entry – SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) to
Read more →VIR▼ -6.7%on this news
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, at 4:05 p.m. ET. A live webcast o
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing operations and liabilities for up to five years – – Company provides update on COVID-19 development program and outlines multi
Read more →VIRVir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022. The corporate update and finan
Read more →VIR▼ -8%on this news
Vir Biotechnology Announces Transition of Chief Scientific Officer
SAN FRANCISCO, July 14, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Herbert “Skip” Virgin, M.D., Ph.D., Vir’s executive vice president, research and chief scientific officer, will step down effective August 31, 2022 to pursue a new position
Read more →VIR▲ +7.3%on this news
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the Phase 2 MARCH trial b
Read more →VIR▼ -5.7%on this news· ran to -17% by day 3
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster presentations at the International Liver Congress™
Read more →VIRVir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20, 2022, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via
Read more →VIR▼ -6.4%on this news
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
– $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the first quarter – – Encouraging initial data from MARCH trial evaluating hepatitis
Read more →VIRVir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 – – Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm ET / 9:00 am PT – SAN FRANCISCO, April 27, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Na
Read more →VIRVir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022. The update will be provided via
Read more →VIR▲ +6.1%on this news
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
SAN FRANCISCO, April 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment community on Wednesday, April 27, from 12:00 – 2:00 p.m. ET. Vir’s Hepatitis Portfolio R&D
Read more →VIRVir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
SAN FRANCISCO, April 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that a team of three company scientists were named one of the winners of the Pediatric COVID-19 Data Challenge, sponsored by the Biomedical Advanced Research and Development Au
Read more →VIRVir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on Monday, April 11, at 11:00 a.m. ET. The conference will be held virtua
Read more →VIR▼ -13.6%on this news
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 SAN FRANCISCO, March 25, 2022 GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Food and Drug Administration has amende
Read more →VIRVir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42nd Annual Cowen Healthcare Conference on Wednesday, March 9, at 10:30 a.m. ET. The confere
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold t
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date $917.2 million of sotrovimab collaboration revenu
Read more →VIR▼ -5.4%on this news
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022. The updat
Read more →VIRVir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global, effective March 2, 2022. Reporting to Vir’s Chief Executive Off
Read more →VIR▼ -5.9%on this news
Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria
– New commitment from the Bill & Melinda Gates Foundation supports the development of Vir’s novel “vaccinal antibody” technology as another important step in the fight to address global infectious diseases – SAN FRANCISCO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc
Read more →VIR▼ -5.8%on this news
Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 p.m. ET. The conference w
Read more →VIRVir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement
– Growing body of evidence validates Vir’s approach of targeting a highly conserved region of the spike protein – – Together with recent pseudo- and live virus results, additional preclinical data reinforce sotrovimab retains in vitro neutralizing activity against all known var
Read more →VIRVir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection
– Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV – SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in a Phase 2 clinic
Read more →VIR▲ +12%on this newsshared move
Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant
SAN FRANCISCO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new data that demonstrates sotrovimab retains activity against the full combination of
Read more →VIRVir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting
– New data from ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate notable reductions in HBsAg and support their positive safety profiles – SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new dat
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results – To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide – – In the
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collabo
Read more →VIRVir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021. The update will be provid
Read more →VIRVir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting 2021
SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the
Read more →VIRVir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference on Wednesday, Oct. 13, at 9:30
Read more →VIRVir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference on Wednesday, Oct. 6, at 11
Read more →VIRVir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, Sept
Read more →VIRVir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, Sept. 13, at 4:00 a.m. PT / 7:00 a
Read more →VIRVir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia
SAN FRANCISCO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product, sotrovimab, developed in partnership with GlaxoSmithKline (GSK). This announcement fol
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results SAN FRANCISCO, August 5, 2021 Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. Vir ma
Read more →VIRVir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021. The update will be provided via
Read more →VIRVir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial evaluating VIR-2218 together with VIR-3434 for the t
Read more →VIRLegal Disclaimers 2021 Vir Biotechnology, Inc. Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include
Vir Biotechnology, Inc. EASL ILC 2021 Hepatitis B Data Call A WORLD WITHOUT INFECTIOUS DISEASE June 25, 2021 Exhibit 99.1 Legal Disclaimers 2021 Vir Biotechnology, Inc. Forward-Looking Statements Statements in this presentation that are not statements of historical fact are fo
Read more →VIRVir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
– Results demonstrate positive safety profiles and a reduction in HBsAg for two novel HBV therapies administrated as monotherapy or in combination with other agents – – Management to host conference call today, Friday, June 25, 2021, at 11:00 a.m. ET – SAN FRANCISCO, June 25, 2
Read more →VIRVir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021
SAN FRANCISCO, June 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting data from its hepatitis B clinical program have been accepted for two oral and two poster presentations at the European Association for the Stud
Read more →VIRVir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June
Read more →VIRGSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients Treatment with sotrovima
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitaliza
Read more →VIRCORRECTION EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology s Sotrovimab For the Early Treatment of COVID-19 Opinion based on the EMA s Committee for Human Medicinal Products (CHMP) review of available
CORRECTION EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology s Sotrovimab For the Early Treatment of COVID-19 Opinion based on the EMA s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early t
Read more →VIRVir Biotechnology Reminds Stockholders of 2021 Annual General Meeting Details
SAN FRANCISCO, May 10, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on Thursday, May 20, 2021, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via liv
Read more →VIRVir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results SAN FRANCISCO, May 6, 2021 - Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. "We've h
Read more →VIRVir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021
SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021. The update will be provided via a
Read more →VIRLegal disclaimers 2021 Vir Biotechnology, Inc. Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include
Vir Biotechnology, Inc. A WORLD WITHOUT INFECTIOUS DISEASE 20th Annual Needham Healthcare Conference April 13, 2021 Exhibit 99.1 Legal disclaimers 2021 Vir Biotechnology, Inc. Forward-Looking Statements Statements in this presentation that are not statements of historical fact
Read more →VIRVir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells
– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations – – Newly identified cell surface proteins play a role in SARS-CoV-2 infection and determine how
Read more →VIRVir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13th
Read more →VIRVir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant
– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern – – Plasma from vaccinated individuals and several therapeutic monoclonal antibodies showed a reduction in neutralization potency
Read more →VIRVir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
– Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or death – – Vir and GSK plan to immediately seek Emergency Use Authorization in the U.S. and authorizations in other countries – – Additional new
Read more →VIRVir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
SAN FRANCISCO and LONDON, March 03, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today provided an update on the VIR-7831 (GSK4182136) arm of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Inte
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results SAN FRANCISCO, February 25, 2021 - Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full y
Read more →VIRGSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Companies applying their combined expertise in immunology and infectious diseases to accelerate the development of promising monoclonal antibody candidates for influen
Read more →VIRVir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021. The update
Read more →VIRVir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics
– Scientists continuing to advance critical research on mechanisms of immune evasion exemplified by emerging SARS-CoV-2 variants – – Study identifies the N-terminal domain of the SARS-CoV-2 spike protein as a target of potent neutralizing antibodies, but a target that can vary –
Read more →VIRInitial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen Novel HBV-neutralizing monoclonal antibody with therapeutic vaccine potential demonstrated a mean HBsAg reduc
Read more →VIRVir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which
Read more →VIRVir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform
SAN FRANCISCO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, announced that the first patient was dosed in late December 2020 in a Phase 1 clinical trial
Read more →VIRVir Biotechnology to Present at 39th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., chief executive officer will virtually present a
Read more →VIRVir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
– Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 – SAN FRANCISCO and LONDON, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline p
Read more →VIRVir Biotechnology Appoints Jeffrey Hatfield to its Board of Directors
SAN FRANCISCO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeffrey Hatfield, an accomplished industry executive with more than three decades of commercial experience, to its Board of Directors. “We are pleased to wel
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results SAN FRANCISCO, November 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious dise
Read more →VIRVir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K
SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new research demonstrating that the immunodominant SARS-CoV-2 receptor binding motif (RBM) is the least conserved region in the SARS-CoV-2 spike protein, allo
Read more →VIRVir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020
SAN FRANCISCO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the
Read more →VIRVir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020
– Preclinical data show VIR-2482 has broad neutralizing potential against all major strains of influenza A from the last 100 years – – Extended half-life observed in Phase 1 demonstrates potential for once-per-season dosing – – Claims-based analysis highlights the high hospita
Read more →VIRVir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference
SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that Phil Pang, M.D., Ph.D., Chief Medical Officer of Vir, and Vasant Jadhav, Ph.D., Vice President, Resear
Read more →VIRVir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2 lead-in Initial Phase 3 results may be available as early as the end of 2020; results for
Read more →VIRVir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell
– Largest-to-date analysis of serum samples from nearly 650 SARS-CoV-2-infected patients – – High-resolution serology advances understanding of variations in natural antibody response to SARS-CoV-2 and paves the way for future development of vaccines/therapies – – Manuscript hi
Read more →VIRA W O R L D W I T H O U T I N F E C T I O U S D I S E A S E Vir Biotechnology, Inc. H.C. Wainwright 22nd Annual Global Investment Conference
A W O R L D W I T H O U T I N F E C T I O U S D I S E A S E Vir Biotechnology, Inc. H.C. Wainwright 22nd Annual Global Investment Conference September 16, 2020 Legal disclaimers Forward-Looking Statements Statements in this presentation that are not statements of historical fac
Read more →VIRVir Biotechnology to Present at Cantor Global Virtual Healthcare Conference
SAN FRANCISCO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., chief medical officer of Vir will present at t
Read more →VIRVir Biotechnology to Present at H.C. Wainwright 22nd Annual Global Investment Conference
SAN FRANCISCO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., chief medical officer of Vir will virtually pr
Read more →VIRVir Biotechnology Appoints Janet Napolitano to its Board of Directors
SAN FRANCISCO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Janet Napolitano to its board of directors. Napolitano brings a breadth of leadership experience in both the public and private sectors to the organization.
Read more →VIRVir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment
Phase 2/3 COMET-ICE study will investigate the safety and efficacy of antibody treatment in preventing hospitalization due to COVID-19 Potential for initial study results to be available before the end of 2020, with early access to the antibody treatment as soon as the first hal
Read more →VIRVir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress™
SAN FRANCISCO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that data from its VIR-2218 clinical program will be featured at the Europea
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results SAN FRANCISCO, August 11, 2020 - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provide
Read more →VIRConfidential Execution Copy 29 July 2020 ASSIGNMENT AND NOVATION AGREEMENT THIS ASSIGNMENT AND NOVATION AGREEMENT (this Agreement ) is made as of
ASSIGNMENT AND NOVATION AGREEMENT THIS ASSIGNMENT AND NOVATION AGREEMENT (this Agreement ) is made as of July 29, 2020 ( Assignment Date ), by and among Vir Biotechnology, Inc., a Delaware corporation having a principal place of business at 499 Illinois Street, Suite 500, San F
Read more →VIRVir Biotechnology to Provide Corporate Update and Report Second Quarter 2020 Financial Results on August 11, 2020
SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the
Read more →VIRVir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors
SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Elliott Sigal, M.D., Ph.D., to its board of directors. Dr. Sigal formerly served as Executive Vice President, Chief Scientific Officer and President of Bristo
Read more →VIRVir Biotechnology Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the closing of its previously announced underwritten public offering of 8,21
Read more →VIRCERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. CONFIDENTIAL EXECUTIO
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. PATENT LICENSE AGREEMENT This PATENT LICENSE AGREEMENT (this Agreement ), effe
Read more →VIRBUSINESS SUMMARY Business Summary Our mission is to create a world without infectious disease We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat a
Our mission is to create a world without infectious disease We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are one of the leading causes of
Read more →VIRVir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment
Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment FRANCISCO May 29, 2020 Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that is has finalized a process development and manufacturing agreement with Biogen I
Read more →VIRVir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the initiation of a Phase 1 clinical trial of VIR-3434, an investigational monoclonal antibody that neutralizes hepatitis B virus (HBV) and has been engineered to potentially als
Read more →VIRVir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results SAN FRANCISCO - May 12, 2020 - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided
Read more →VIRVir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the h
Read more →VIRVir Biotechnology to Present at BofA Securities 2020 Health Care Conference
SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., Chief Executive Officer will virtually present at
Read more →VIRVir Biotechnology to Provide Corporate Update and Report First Quarter 2020 Financial Results on May 12, 2020
SAN FRANCISCO, April 28, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for th
Read more →VIRVIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial
SAN FRANCISCO, April 15, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR) today announced additional interim data from the ongoing Phase 2 trial in patients and results from the Phase 1 trial in healthy volunteers of VIR-2218, an investigational small interfering ri
Read more →VIRRelease Date: 10 April 2020 Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment SONGDO, S. KOREA and SAN FRANCISCO US, 10 Apr
Release Date: 10 April 2020 Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment SONGDO, S. KOREA and SAN FRANCISCO US, 10 April 2020 Samsung Biologics (207940.KS) and Vir Biotechnolo
Read more →VIRVir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218
SAN FRANCISCO, April 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will host a Key Opinion Leader call and present an update on its Ph
Read more →VIRFor media and investors only Issued
Issued: April 6, 2020, London UK and San Francisco US GSK and Vir Biotechnology enter collaboration to find coronavirus solutions GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to enter into a
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results SAN FRANCISCO - March 26, 2020 - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases
Read more →VIRVir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19
- Multiple antibodies identified that neutralize SARS-CoV-2 - Phase 1/2 clinical testing planned for this summer SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has identified multiple human monoclonal antibody (mA
Read more →VIRVir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19
SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has signed a letter of intent with Biogen Inc. (Nasdaq: BIIB) for the development and clinical manufacturing of human monoclonal antibodies for the potential treatment
Read more →VIRVir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses
SAN FRANCISCO, March 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced a research collaboration agreement with the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (
Read more →VIRVir Biotechnology to Present at Barclays Global Healthcare Conference
SAN FRANCISCO, March 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., Chief Medical Officer wil
Read more →VIRVir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19
SAN FRANCISCO and SHANGHAI, China, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and WuXi Biologics (stock code: 2269.HK) today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential t
Read more →VIRVir Biotechnology to Present at 40th Annual Cowen Healthcare Conference
SAN FRANCISCO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., Chief Executive Officer wil
Read more →VIRVir Biotechnology Identifies Two Antibodies That Bind to The Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2
Vir Biotechnology Identifies Two Antibodies That Bind to The Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2 SAN FRANCISCO February 12, 2020 - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventi
Read more →VIRVir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus
Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus SAN FRANCISCO January 22, 2020 - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infect
Read more →VIRVir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, will present tomorrow, January 14
Read more →VIRVir Biotechnology to Present at 38th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, today announced that George Scang
Read more →VIRVir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results SAN FRANCISCO, Calif. - November 19, 2019 - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge techno
Read more →VIRVir Biotechnology Announces Pricing of Initial Public Offering
SAN FRANCISCO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, announced today that it has price
Read more →Competitive Position
How VIR ranks across every disease it competes inCompetitive Position is a premium feature
See how VIR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial